» Articles » PMID: 18505426

Reduction of Forkhead Box P3 Levels in CD4+CD25high T Cells in Patients with New-onset Systemic Lupus Erythematosus

Overview
Date 2008 May 29
PMID 18505426
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to quantify and evaluate the forkhead box P3 (FoxP3) expression regulatory T cells in new-onset systemic lupus erythematosus (SLE) patients before and after treatment. Forty-four newly diagnosed and untreated SLE patients, including 24 with active disease (SLEDAI > or = 10) and 20 with inactive disease (SLEDAI < 5), were enrolled in this study. Twenty-one age- and sex-matched healthy volunteers were also included as controls. Peripheral blood samples were collected and mononuclear cells isolated. The expression of CD25 and FoxP3 in CD4(+) T cells were analysed with flow cytometry. CD4(+)CD25(+) (3.95-13.04%) and CD4(+)CD25(high) (0.04-1.34%) T cells in peripheral blood in untreated patients with new-onset active lupus were significantly lower than that in the patients with inactive lupus (7.27-24.48%, P < 0.05 and 0.14-3.07% P < 0.01 respectively) and that in healthy controls (5.84-14.84%, P < 0.05). Interestingly, the decrease in CD4(+)CD25(high) T cells was restored significantly in patients with active lupus after corticosteroid treatment. There was, however, a significantly higher percentage of CD4(+)FoxP3(+) T cells in patients with active (5.30-23.00%) and inactive (7.46-17.38%) new-onset lupus patients compared with healthy control subjects (2.51-12.94%) (P < 0.01). Intriguingly, CD25 expression in CD4(+)FoxP3(+) T cells in patients with active lupus (25.24-62.47%) was significantly lower than that in those patients with inactive lupus (30.35-75.25%, P < 0.05) and healthy controls (54.83-86.38%, P < 0.01). Most strikingly, the levels of FoxP3 expression determined by mean fluorescence intensity in CD4(+)CD25(high) cells in patients with active SLE were significantly down-regulated compared with healthy subjects (130 +/- 22 versus 162 +/- 21, P = 0.012). CD4(+)CD25(high) T cells are low in new-onset patients with active SLE and restored after treatment. Despite that the percentage of CD4(+)FoxP3(+) T cells appear high, the levels of FoxP3 expression in CD4(+)CD25(high) T cells are down-regulated in untreated lupus patients. There is a disproportional expression between CD25(high) and FoxP3(+) in new-onset patients with active SLE.

Citing Articles

Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.

Tomasovic L, Liu K, VanDyke D, Fabilane C, Spangler J BioDrugs. 2023; 38(2):227-248.

PMID: 37999893 PMC: 10947368. DOI: 10.1007/s40259-023-00635-0.


T cells in health and disease.

Sun L, Su Y, Jiao A, Wang X, Zhang B Signal Transduct Target Ther. 2023; 8(1):235.

PMID: 37332039 PMC: 10277291. DOI: 10.1038/s41392-023-01471-y.


Regulatory T cell function in autoimmune disease.

Rajendeeran A, Tenbrock K J Transl Autoimmun. 2022; 4:100130.

PMID: 35005594 PMC: 8716637. DOI: 10.1016/j.jtauto.2021.100130.


Prostaglandin E directly inhibits the conversion of inducible regulatory T cells through EP2 and EP4 receptors via antagonizing TGF-β signalling.

Goepp M, Crittenden S, Zhou Y, Rossi A, Narumiya S, Yao C Immunology. 2021; 164(4):777-791.

PMID: 34529833 PMC: 8561111. DOI: 10.1111/imm.13417.


Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease.

Thome A, Atassi F, Wang J, Faridar A, Zhao W, Thonhoff J NPJ Parkinsons Dis. 2021; 7(1):41.

PMID: 33986285 PMC: 8119976. DOI: 10.1038/s41531-021-00188-5.


References
1.
Nishimura E, Sakihama T, Setoguchi R, Tanaka K, Sakaguchi S . Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells. Int Immunol. 2004; 16(8):1189-201. DOI: 10.1093/intimm/dxh122. View

2.
Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan K, George S . Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine. 2006; 35(3-4):148-53. DOI: 10.1016/j.cyto.2006.07.023. View

3.
Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S . Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol. 2005; 175(12):8392-400. DOI: 10.4049/jimmunol.175.12.8392. View

4.
Brusko T, Wasserfall C, Clare-Salzler M, Schatz D, Atkinson M . Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes. 2005; 54(5):1407-14. DOI: 10.2337/diabetes.54.5.1407. View

5.
Lawson C, Brown A, Bejarano V, Douglas S, Burgoyne C, Greenstein A . Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology (Oxford). 2006; 45(10):1210-7. DOI: 10.1093/rheumatology/kel089. View